RxDoctor Payments DataLook up a doctor →

Mark Napoli, MD

Interventional Cardiology · Monroe, LANPI 1811984537

Payments from drug & device makers

$2,217,241in general payments, 2019–2025

Across 1,332 payments — averaging $1664.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$671K
  • Eli Lilly$527K
  • Novartis$366K
  • Merck$152K
  • Boehringer Ingelheim International GmbH$133K
  • Janssen Research & Development, LLC$123K
  • plus $245K from 37 others
$128,757in research payments, 2019–2025

Across 3 payments — averaging $42,919 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$129K

What the payments were for

  • Travel & lodging$1,1529%
  • Food & beverage$12,36091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,217,241 in reported general payments places this provider in the 95th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$1,067,840
Medicare patients
2,708
Services billed
11,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban139$108,210
EntrestoSacubitril/Valsartan63$46,604
Repatha SureclickEvolocumab48$37,848
XareltoRivaroxaban40$24,783
JardianceEmpagliflozin29$19,319
NexlizetBempedoic Acid/Ezetimibe23$9,078
Rosuvastatin Calcium296$4,851
Ezetimibe144$4,028
Amiodarone Hcl107$3,802
Atorvastatin Calcium223$3,300
Losartan Potassium199$2,563
Ranolazine ErRanolazine37$2,177
SotalolSotalol Hcl111$1,371
Flecainide Acetate19$1,352
ClopidogrelClopidogrel Bisulfate109$1,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33,214$108,210139 claims
NovartisEntresto$366,388$46,60463 claims
Johnson & JohnsonXarelto$879$24,78340 claims
Boehringer IngelheimJardiance$20,175$19,31929 claims
Esperion Therapeutics, Inc.Nexlizet$285$9,07823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →